Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.
about
The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease InhibitorsA Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In VitroTargeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaOmeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cellsTwo-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumDrug synergy drives conserved pathways to increase fission yeast lifespanNLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised LearningExploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphomaThe mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cellsComparison of methods for evaluating drug-drug interaction.An evaluation of remifentanil-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrationsThe triple combination indinavir-zidovudine-lamivudine is highly synergistic.In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesGender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activityDevelopment, evaluation, and application of an in silico model for antimalarial drug treatment and failure.Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosaEffects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.Combination treatment of invasive fungal infections.Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death.Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesReducing signs of aging and increasing lifespan by drug synergy.A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityA Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studiesSynergistic effects of floral phytochemicals against a bumble bee parasite.Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.Method to Assess Interactivity of Drugs with Nonparallel Concentration-Effect Relationships.Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of SeliciclibAssessment of non-linear combination effect terms for drug-drug interactions.Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.Translational PK/PD of anti-infective therapeutics.Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.Drug interaction: focusing on response surface models.BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action.
P2860
Q27485895-D23B5CC7-9733-479E-9EBA-5739BAE6BDF0Q27490546-E5985A99-2B1E-432D-A958-A990BCC0A7B6Q28115962-EE208FB3-C283-4AF8-BFA9-150A1B5DAEC0Q28478262-82CF59A1-5960-4D8E-B700-8275AE6667F8Q28478890-E4CE10A7-4B7F-4481-9C82-F093302119D4Q28544630-20BFEBF9-FDEE-4D21-A7D0-0F1196AA3657Q28552626-9C6A62A8-8930-4305-BB4C-41D8A615B562Q28649793-95179ADA-5D47-488D-A404-A902CA6B42B0Q33676981-1D34E543-8CD1-4B89-AF09-2B8DB6F718ECQ33914266-110688C4-E7CB-4553-9B05-89CCE7CB2321Q33925609-97C0B283-C332-4775-96EF-8A32556F458CQ33979237-A45F2480-5771-496B-A36C-44B8DB39A8F2Q34143259-719E8320-1E8A-4EEF-A4F6-ABD69BD85D22Q34287755-097BC5A3-1A8F-4993-9A59-5DDED956B9C3Q34392896-41B74001-35A8-4D4B-8CCC-9063DD684798Q34585809-C36348D5-8872-4A46-AAD1-13C732735D56Q35065737-942D72F5-E8BD-4FBE-BDCB-592D00C05AE3Q35123092-A56E6636-029C-411E-B877-EB09C5B2B9C4Q35645883-0653E87C-16B5-43EB-B189-E66B73B4C60FQ36011378-7E9F2E47-6BE9-43B3-9607-0728AC3A0052Q36291554-BE5F6D31-6B0B-4BA9-9797-5E0F709E0C9CQ36849233-4472CCC0-C3DD-490F-B8A3-3B3249527436Q37022133-7CC77465-E254-426F-AC18-25474F094B31Q37034317-D612FD78-EC63-41C0-A529-55A46A84F0C0Q37089235-795F647A-7EDA-4257-9B3E-329CF55F364EQ37173701-0D228F38-EDCD-4C16-95BD-B95C69289BB2Q37706796-C170CA45-8372-46EF-81FC-4D54ACD73181Q38848491-E29C73A8-ECCE-464F-98EF-71C876C308E9Q38866872-6E3616B6-535E-4B93-8D51-B5B3B9BF2BB2Q38877559-67CD7D21-283E-4380-8242-B20E06015F6FQ38957295-98786B3E-79F2-4EFE-90A2-C200EB171070Q39013265-D85AD70E-17B2-4B06-B0C8-690B56F74BFEQ39039505-C643ED6A-8766-49A8-A70A-2622630608E4Q39478859-131330C2-D35F-40A8-9424-88D7CA1D2BFCQ39730865-3A687329-F7F1-47A6-BAA4-0711701820C2Q39743397-9F1D6A5B-A97D-42DF-A8E9-4CFF9F97D3EFQ40155324-04C1CDC8-8409-4785-BB64-3DF89D2F7555Q40291140-E946D187-3469-4CCC-9346-C99E46EE242BQ40907848-91DA12FD-577C-4C7F-8ED1-60DD35BCED0AQ41244127-5C19FF57-2C40-49B6-A88F-17D4E883F65D
P2860
Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@en
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@nl
type
label
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@en
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@nl
prefLabel
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@en
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@nl
P2093
P1433
P1476
Application of a new approach ...... ta-D-arabinofuranosylcytosine.
@en
P2093
P304
P407
P577
1990-09-01T00:00:00Z